Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 9/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.54 |
| ▸ | NPY1R | P25929 | 7/20 | 0.54 |
| ▸ | NPY2R | P49146 | 5/20 | 0.54 |
| ▸ | IL23R | Q5VWK5 | 6/20 | 0.54 |
| ▸ | TFPI | P10646 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30512544 | 0.89 | NPY4R (0.55) | NPY4RNPY5RNPY1RNPY2RIL23R | |
| SCHEMBL30865071 | 0.89 | TFPI (0.61) | NPY4RNPY5RNPY1RNPY2RIL23R | |
| SCHEMBL29993877 | 0.87 | NPY4R (0.65) | NPY4RNPY5RNPY1RNPY2RTFPI | |
| SCHEMBL30429246 | 0.87 | TFPI (0.61) | NPY4RNPY5RNPY1RNPY2RIL23R | |
| SCHEMBL30880895 | 0.86 | OPRM1 (0.60) | NPY4RNPY5RNPY1RNPY2RIL23R | |
| SCHEMBL31683267 | 0.86 | TFPI (0.61) | NPY4RNPY5RNPY1RNPY2RTFPI | |
| SCHEMBL30865075 | 0.86 | TFPI (0.60) | NPY4RNPY5RNPY1RNPY2RIL23R | |
| SCHEMBL30184327 | 0.86 | TFPI (0.60) | NPY4RNPY5RNPY1RNPY2RIL23R | |
| SCHEMBL9074145 | 0.86 | TFPI (0.69) | IL23RTFPIOPRM1OPRD1OPRK1 | |
| SCHEMBL30184205 | 0.85 | OPRM1 (0.61) | NPY4RNPY5RNPY1RNPY2RIL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570729-B2 | Antibody fragment based antifungal conjugate selectively targeting candida | ABGENICS LIFESCIENCES PRIVATE LIMITED (IN) | 2026-03-10 | — | — | US | disclosed |
| US-20240092878-A1 | AN ANTIBODY FRAGMENT BASED ANTIFUNGAL CONJUGATE SELECTIVELY TARGETING CANDIDA | ABGENICS LIFESCIENCES PRIVATE LIMITED (IN) | 2024-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570729-B2 | Antibody fragment based antifungal conjugate selectively targeting candida | SERPINH1, HM13, NGLY1 | NPY4R 4140/4885NPY5R 2290/4885NPY1R 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.